166 related articles for article (PubMed ID: 38785958)
1. 4-Hydroxy-1α,25-Dihydroxyvitamin D
Peluso-Iltis C; Pierrat N; Rovito D; Osz J; Sawada D; Kittaka A; Laverny G; Rochel N
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785958
[TBL] [Abstract][Full Text] [Related]
2. Nongenomic effects of 1α,25-dihydroxyvitamin D
Hirota Y; Nakagawa K; Mimatsu S; Sawada N; Sakaki T; Kubodera N; Kamao M; Tsugawa N; Suhara Y; Okano T
Biochem Biophys Res Commun; 2017 Jan; 483(1):359-365. PubMed ID: 28025137
[TBL] [Abstract][Full Text] [Related]
3. 25(OH)D
Kikuyama T; Susa T; Tamamori-Adachi M; Iizuka M; Akimoto M; Okinaga H; Fujigaki Y; Uchida S; Shibata S; Okazaki T
J Steroid Biochem Mol Biol; 2020 May; 199():105593. PubMed ID: 31945466
[TBL] [Abstract][Full Text] [Related]
4. Without 1α-hydroxylation, the gene expression profile of 25(OH)D
Susa T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
Sci Rep; 2018 Jun; 8(1):9024. PubMed ID: 29899561
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D-induced ectodomain shedding of TNF receptor 1 as a nongenomic action: D3 vs D2 derivatives.
Yang WS; Yu H; Kim JJ; Lee MJ; Park SK
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):18-25. PubMed ID: 26385608
[TBL] [Abstract][Full Text] [Related]
6. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ.
Slominski AT; Kim TK; Hobrath JV; Oak ASW; Tang EKY; Tieu EW; Li W; Tuckey RC; Jetten AM
J Steroid Biochem Mol Biol; 2017 Oct; 173():42-56. PubMed ID: 27693422
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and metabolic studies of 1α,2α,25-, 1α,4α,25- and 1α,4β,25-trihydroxyvitamin D3.
Takano M; Sawada D; Yasuda K; Nishikawa M; Takeuchi A; Takagi K; Horie K; Reddy GS; Chen TC; Sakaki T; Kittaka A
J Steroid Biochem Mol Biol; 2015 Apr; 148():34-7. PubMed ID: 25263656
[TBL] [Abstract][Full Text] [Related]
8. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
[TBL] [Abstract][Full Text] [Related]
9. 25-Dehydro-1alpha-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change.
Bula CM; Bishop JE; Ishizuka S; Norman AW
Mol Endocrinol; 2000 Nov; 14(11):1788-96. PubMed ID: 11075812
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.
Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M
J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646
[TBL] [Abstract][Full Text] [Related]
11. The 3-epi- and 24-oxo-derivatives of 1alpha,25 dihydroxyvitamin D(3) stimulate transcription through the vitamin D receptor.
Messerlian S; Gao X; St-Arnaud R
J Steroid Biochem Mol Biol; 2000; 72(1-2):29-34. PubMed ID: 10731635
[TBL] [Abstract][Full Text] [Related]
12. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
13. Functionalization at C-12 of 1alpha,25-dihydroxyvitamin D(3) strongly modulates the affinity for the vitamin D receptor (VDR).
González-Avión XC; Mouriño A
Org Lett; 2003 Jun; 5(13):2291-3. PubMed ID: 12816431
[TBL] [Abstract][Full Text] [Related]
14. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs.
Peleg S; Nguyen C; Woodard BT; Lee JK; Posner GH
Mol Endocrinol; 1998 Apr; 12(4):525-35. PubMed ID: 9544988
[TBL] [Abstract][Full Text] [Related]
15. Carboxylic ester antagonists of 1alpha,25-dihydroxyvitamin D(3) show cell-specific actions.
Herdick M; Steinmeyer A; Carlberg C
Chem Biol; 2000 Nov; 7(11):885-94. PubMed ID: 11094341
[TBL] [Abstract][Full Text] [Related]
16. Calcioic acid: In vivo detection and quantification of the terminal C24-oxidation product of 25-hydroxyvitamin D
Kaufmann M; Martineau C; Arabian A; Traynor M; St-Arnaud R; Jones G
J Steroid Biochem Mol Biol; 2019 Apr; 188():23-28. PubMed ID: 30553931
[TBL] [Abstract][Full Text] [Related]
17. Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications.
Kaya T; Swamy N; Persons KS; Ray S; Mohr SC; Ray R
Bioorg Chem; 2009 Apr; 37(2):57-63. PubMed ID: 19223058
[TBL] [Abstract][Full Text] [Related]
18. Cytosolic sequestration of the vitamin D receptor as a therapeutic option for vitamin D-induced hypercalcemia.
Rovito D; Belorusova AY; Chalhoub S; Rerra AI; Guiot E; Molin A; Linglart A; Rochel N; Laverny G; Metzger D
Nat Commun; 2020 Dec; 11(1):6249. PubMed ID: 33288743
[TBL] [Abstract][Full Text] [Related]
19. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
20. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor.
Liu YY; Nguyen C; Peleg S
Mol Endocrinol; 2000 Nov; 14(11):1776-87. PubMed ID: 11075811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
